UpcomingPDUFA target action date

Zipalertinib

Taiho Oncology / Cullinan Therapeutics (CGEM)

Marketer take

Would enter EGFR exon 20 insertion lung cancer, a niche where amivantamab-based regimens are established, so biomarker testing rates and thoracic oncologist reach set the size of the opportunity.

Sponsor company
Taiho Oncology / Cullinan Therapeutics (CGEM)
Indication
Relapsed EGFR exon 20 insertion non-small cell lung cancer
Therapeutic area
Oncology
Event
PDUFA target action date
Date
Feb 27, 2027
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move